USANA Health Sciences (NYSE:USNA) Lowered to “Hold” Rating by Zacks Research

Zacks Research downgraded shares of USANA Health Sciences (NYSE:USNA) from a strong-buy rating to a hold rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

USNA has been the subject of a number of other research reports. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

USANA Health Sciences Trading Down 1.5%

Shares of USNA stock opened at $19.23 on Wednesday. The firm has a fifty day moving average price of $18.69 and a 200 day moving average price of $19.95. The company has a market cap of $354.91 million, a P/E ratio of 34.96, a PEG ratio of 0.83 and a beta of 0.71. USANA Health Sciences has a 12 month low of $16.60 and a 12 month high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. The firm had revenue of $226.20 million during the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. On average, equities analysts forecast that USANA Health Sciences will post 1.95 EPS for the current year.

Insiders Place Their Bets

In related news, insider Joshua Foukas sold 4,461 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $21.34, for a total value of $95,197.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of USNA. Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences in the fourth quarter valued at $11,485,000. Millennium Management LLC lifted its position in USANA Health Sciences by 715.7% in the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock valued at $5,603,000 after acquiring an additional 250,424 shares during the last quarter. Two Sigma Investments LP lifted its position in USANA Health Sciences by 349.8% in the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after acquiring an additional 125,158 shares during the last quarter. UBS Group AG lifted its position in USANA Health Sciences by 252.3% in the fourth quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after acquiring an additional 99,063 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its position in USANA Health Sciences by 354.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after acquiring an additional 85,570 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.